We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Rapid POC Screening Technology Uses Artificial Glycan Receptor to Detect Coronavirus in 20 Minutes

By LabMedica International staff writers
Posted on 28 Mar 2020
Iceni Diagnostics (Norwich, UK), a biotechnology company, is developing a new approach that identifies the virus not by its genetic code, which can mutate, but by using its reliance on chains of sugars which are constant and unchangeable. More...
The existing prototype product for influenza can detect the virus in less than 20 minutes and could be adapted to identify other pathogens, such as the coronavirus.

Iceni Diagnostics is focused on the development of carbohydrate-based therapeutics and point-of-care diagnostics for infectious diseases. Capitalizing on its expertise in carbohydrate and analytical chemistry, it provides bespoke solutions in glycoscience R&D, nanoparticle technology and bioconjugation chemistry. Iceni Diagnostics is developing a portfolio of in-house programs, as well as engaging in collaborative and contract R&D activities, through engagement with the UK biotech sector and government research organizations. Its current projects include the development of novel point-of-care diagnostics and new chemical and enzymatic approaches to the production of carbohydrate-containing biopharmaceuticals.
Viruses typically invade the body through cells in the respiratory tract. These cells are covered in a coat of sugar chains, known as glycans, which are used to recognize beneficial substances. Viruses can utilize these glycans as part of the infection process. This process can also be used in reverse to identify the virus in saliva or nasal fluids. Iceni Diagnostics’ diagnostic technique uses an artificial glycan receptor to capture the virus.

Iceni Diagnostics has already developed a series of prototype products that can specifically detect pathogens such as Norovirus and different strains of influenza in less than 20 minutes. The most advanced product, for equine influenza, is performing well in early stage clinical trials. The hand-held device uses lateral flow – like a home pregnancy test – to give a simple yes/no answer. It requires no refrigeration and no training, meaning the test is usable in any location, by any person, in order to detect flu or other pathogens.

Iceni Diagnostics’ current products detect a single virus. However, the next generation of diagnostics will enable the detection and discrimination of a series of pathogens that give rise to similar symptoms. This would enable, for example, a distinction between flu and COVID-19 in a single sample, increasing the versatility and robustness of the diagnosis. Additionally, the way the virus interacts with its glycan receptor makes it seasonally consistent, so, even if the virus genetic code mutates, it will still be detected – meaning that Iceni Diagnostics’ test should remain effective indefinitely. In an industry dominated by protein/DNA technology the glycan-based platform offers opportunities for the development of novel medicines and tests.

“The Iceni Diagnostics approach uses glycan recognition, which is unaffected by seasonal variation in the genetic code, and can be offered as a handheld home or field-based test,” said Professor Rob Field, Director of the Manchester Institute of Biotechnology and the co-founder of Iceni Diagnostics. “This new approach, which is based on host-pathogen glycan recognition could potentially result in a more universal detection technique, crucial in early diagnostics of outbreaks.”

Related Links:
Iceni Diagnostics


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.